NZ754218A - Fgfr4 inhibitor and preparation method and use thereof - Google Patents
Fgfr4 inhibitor and preparation method and use thereof Download PDFInfo
- Publication number
- NZ754218A NZ754218A NZ754218A NZ75421817A NZ754218A NZ 754218 A NZ754218 A NZ 754218A NZ 754218 A NZ754218 A NZ 754218A NZ 75421817 A NZ75421817 A NZ 75421817A NZ 754218 A NZ754218 A NZ 754218A
- Authority
- NZ
- New Zealand
- Prior art keywords
- mmol
- group
- compound
- give
- reaction
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/42—One nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
- C07D213/44—Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
- C07D213/53—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/72—Nitrogen atoms
- C07D213/74—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Pyridine Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611012431 | 2016-11-17 | ||
| PCT/CN2017/111634 WO2018090973A1 (zh) | 2016-11-17 | 2017-11-17 | Fgfr4抑制剂及其制备方法和应用 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NZ754218A true NZ754218A (en) | 2021-07-30 |
Family
ID=62145242
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NZ754218A NZ754218A (en) | 2016-11-17 | 2017-11-17 | Fgfr4 inhibitor and preparation method and use thereof |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11008292B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3543227B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP7063899B2 (cg-RX-API-DMAC7.html) |
| KR (1) | KR102249632B1 (cg-RX-API-DMAC7.html) |
| CN (1) | CN109952290B (cg-RX-API-DMAC7.html) |
| AU (1) | AU2017359819B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3043948C (cg-RX-API-DMAC7.html) |
| IL (1) | IL266659B (cg-RX-API-DMAC7.html) |
| MX (1) | MX389403B (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ754218A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2018090973A1 (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA201903845B (cg-RX-API-DMAC7.html) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL274274B2 (en) * | 2017-11-01 | 2023-11-01 | Guangdong Zhongsheng Pharmaceutical Co Ltd | Salt form and crystal form of compound as fgfr4 inhibitor and preparation method thereof |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101003514A (zh) | 2006-01-20 | 2007-07-25 | 上海艾力斯医药科技有限公司 | 喹唑啉衍生物、其制备方法及用途 |
| CN102731485B (zh) | 2011-04-02 | 2016-06-15 | 齐鲁制药有限公司 | 4-(取代苯氨基)喹唑啉衍生物及其制备方法、药物组合物和用途 |
| CN109627239B (zh) | 2012-07-11 | 2021-10-12 | 缆图药品公司 | 成纤维细胞生长因子受体的抑制剂 |
| WO2014139145A1 (en) * | 2013-03-15 | 2014-09-18 | Hutchison Medipharma Limited | Novel pyrimidine and pyridine compounds and usage thereof |
| PH12016500676B1 (en) * | 2013-10-18 | 2022-07-20 | Eisai R&D Man Co Ltd | Pyrimidine fgfr4 inhibitors |
| WO2016115412A1 (en) | 2015-01-18 | 2016-07-21 | Newave Pharmaceutical Llc | Dual-warhead covalent inhibitors of fgfr-4 |
| WO2016164703A1 (en) * | 2015-04-09 | 2016-10-13 | Eisai R & D Management Co., Ltd. | Fgfr4 inhibitors |
| AU2016248056B2 (en) | 2015-04-14 | 2020-07-23 | Eisai R&D Management Co., Ltd. | Crystalline FGFR4 inhibitor compound and uses thereof |
| IL274274B2 (en) * | 2017-11-01 | 2023-11-01 | Guangdong Zhongsheng Pharmaceutical Co Ltd | Salt form and crystal form of compound as fgfr4 inhibitor and preparation method thereof |
-
2017
- 2017-11-17 AU AU2017359819A patent/AU2017359819B2/en active Active
- 2017-11-17 EP EP17871196.6A patent/EP3543227B1/en active Active
- 2017-11-17 NZ NZ754218A patent/NZ754218A/en active IP Right Revival
- 2017-11-17 CN CN201780070537.7A patent/CN109952290B/zh active Active
- 2017-11-17 US US16/461,373 patent/US11008292B2/en active Active
- 2017-11-17 WO PCT/CN2017/111634 patent/WO2018090973A1/zh not_active Ceased
- 2017-11-17 KR KR1020197016780A patent/KR102249632B1/ko active Active
- 2017-11-17 JP JP2019526465A patent/JP7063899B2/ja active Active
- 2017-11-17 CA CA3043948A patent/CA3043948C/en active Active
- 2017-11-17 MX MX2019005723A patent/MX389403B/es unknown
-
2019
- 2019-05-15 IL IL266659A patent/IL266659B/en unknown
- 2019-06-13 ZA ZA2019/03845A patent/ZA201903845B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20200062716A1 (en) | 2020-02-27 |
| WO2018090973A1 (zh) | 2018-05-24 |
| IL266659B (en) | 2022-01-01 |
| JP2019537613A (ja) | 2019-12-26 |
| JP7063899B2 (ja) | 2022-05-09 |
| CN109952290A (zh) | 2019-06-28 |
| CA3043948C (en) | 2021-08-31 |
| MX389403B (es) | 2025-03-20 |
| EP3543227B1 (en) | 2020-12-30 |
| EP3543227A1 (en) | 2019-09-25 |
| CA3043948A1 (en) | 2018-05-24 |
| AU2017359819A1 (en) | 2019-06-20 |
| IL266659A (en) | 2019-07-31 |
| US11008292B2 (en) | 2021-05-18 |
| EP3543227A4 (en) | 2019-10-30 |
| KR20190077085A (ko) | 2019-07-02 |
| AU2017359819B2 (en) | 2020-05-28 |
| MX2019005723A (es) | 2019-10-21 |
| KR102249632B1 (ko) | 2021-05-10 |
| CN109952290B (zh) | 2022-05-03 |
| ZA201903845B (en) | 2020-12-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3290418B1 (en) | Janus kinase (jak) inhibitors | |
| JP7168149B2 (ja) | Ｆｇｆｒ阻害剤としてのピラジン－２（１ｈ）－オン系化合物 | |
| EP3333157B1 (en) | Vinyl compounds as fgfr and vegfr inhibitors | |
| CN113286794A (zh) | Kras突变蛋白抑制剂 | |
| CA3128062A1 (en) | Benzopyridone heterocyclic compound and use thereof | |
| KR102359993B1 (ko) | 피리미도[5,4-b]인돌리진 또는 피리미도[5,4-b]피롤리진 화합물, 그의 제조방법 및 용도 | |
| AU2019296085B2 (en) | Heterocyclic compound as TRK inhibitor | |
| ES2686747T3 (es) | Derivados de 4,5,6,7-tetrahidro-pirazolo[1,5-a]pirimidina y derivados de 2,3-dihidro-1H-imidazo[1,2-b]pirazol sustituidos como inhibidores de ROS1 | |
| CN103476776B (zh) | 作为FAK/Pyk2抑制剂的2,4-二氨基-6,7-二氢-5H-吡咯并[2,3]嘧啶衍生物 | |
| AU2015276699B2 (en) | Pyridino[1,2-a]pyrimidone analogue used as PI3K inhibitor | |
| KR20130122778A (ko) | FAK/Pyk2 억제제인 2,4-디아미노-6,7-디히드로-5H-피롤로[2,3]피리미딘 유도체 | |
| AU2013212175A1 (en) | Azaheterocyclic compounds | |
| KR20200096261A (ko) | 설폰아마이드 화합물 및 이의 용도 | |
| EP4055013B1 (en) | Wdr5 inhibitors and modulators | |
| CA3145344A1 (en) | Pyrazolopyrimidine compound, preparation method for same and applications thereof | |
| EP3543227B1 (en) | Fgfr4 inhibitor and preparation method and use thereof | |
| EP3766883B1 (en) | Imidaxopyrolone compound and application thereof | |
| HK40004140B (en) | Fgfr4 inhibitor and preparation method and use thereof | |
| HK40004140A (en) | Fgfr4 inhibitor and preparation method and use thereof | |
| WO2020247679A1 (en) | Wdr5 inhibitors and modulators |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| ERR | Error or correction |
Free format text: THE TITLE HAS BEEN CORRECTED TO TITLE: FGFR4 INHIBITOR AND PREPARATION METHOD AND USE THEREOF; FILING DATE: 04 JUN 2019; STATUS: PROPOSED; KIND CODE: A1 PUBLICATION DATE: 28 JUN 2019; Effective date: 20200831 |
|
| S35A | Application for proceedings under section 35 (restoration of lapsed patents) | ||
| S35R | Proceedings under section 35 (restoration of lapsed patents): patent restored | ||
| PSEA | Patent sealed | ||
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 NOV 2023 BY ACUMASS Effective date: 20221014 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 NOV 2024 BY ACUMASS Effective date: 20231019 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 NOV 2025 BY OLIVIER BARLOY Effective date: 20241023 |
|
| RENW | Renewal (renewal fees accepted) |
Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 17 NOV 2026 BY ACUMASS Effective date: 20251017 |